Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at the CIBC 19th Annual Eastern Institutional Investor Conference on Thursday, September 17, 2020 at 2:40 p.m. EDT.

Link:
Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference

Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16. During the conference, Nancy Chang, Ph.D., chief executive officer of Ansun, will deliver a corporate update to potential investors registered for the meeting. The corporate update will cover recent and upcoming company milestones, as well as detail clinical progress of the company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases, including influenza and parainfluenza, by preventing viral entry into respiratory epithelial cells. Ansun is also assessing DAS181 in patients with severe COVID-19 in Phase 2 studies.

Read the original post:
Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program

Company announcement – No. 49 / 2020

Original post:
Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program

Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020

LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020

Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging (ASI) California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.

Read more here:
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow

GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogenshelps health care professionals prepare for flu season

Here is the original post:
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Purity-IQ Partners with First North American Testing Labs

Accredited Cannabis Labs Support Cannabis Industry Certification Program Accredited Cannabis Labs Support Cannabis Industry Certification Program

See the original post:
Purity-IQ Partners with First North American Testing Labs

Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.

Excerpt from:
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

Read more from the original source:
Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

Private placement of existing shares and major shareholder announcement

Company announcement no. 32 - 20 14 September 2020

See the article here:
Private placement of existing shares and major shareholder announcement